[Medical treatment of pulmonary hypertension: what's new?]. / Medikamentöse Therapie der pulmonalen Hypertonie: Was ist neu?
Internist (Berl)
; 56(5): 573-82, 2015 May.
Article
em De
| MEDLINE
| ID: mdl-25924799
Pulmonary hypertension (PH) is a chronic progressive disease of the pulmonary circulation of multifactorial causes. The current diagnostic classification of PH distinguishes five main groups, which have as a common feature an increased pulmonary arterial pressure and pulmonary resistance. The classification differentiates pulmonary arterial hypertension (PAH), PH due to left heart disease, PH in lung diseases and/or hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH), and PH with unclear/multifactorial mechanisms. Recent advances in basic research with the approval of new drugs and the establishment of therapeutic strategies, mainly in PAH and CTEPH, require a differentiated view of the disease, a careful diagnosis and initiation of therapy, and regular follow-ups. In this article, we provide an overview of the complex drug therapy currently available for PAH patients.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Prostaglandinas
/
Receptores Citoplasmáticos e Nucleares
/
Inibidores da Fosfodiesterase 5
/
Antagonistas dos Receptores de Endotelina
/
Hipertensão Pulmonar
/
Anti-Hipertensivos
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
De
Revista:
Internist (Berl)
Ano de publicação:
2015
Tipo de documento:
Article